Evidence map›Paper›PMID 30128942›Full record

ArticleClinical and experimental nephrology2019

GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study.

Andrea Schmidts, Julian Grünewald, Martina Kleber, Evangelos Terpos, Gabriele Ihorst, Heike Reinhardt, Gerd Walz, Ralph Wäsch, Monika Engelhardt, Stefan Zschiedrich

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Andrea SchmidtsDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Julian GrünewaldDepartment of Nephrology and Primary Care, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Martina KleberDivisions of Hematology, University Hospital Basel, Basel, Switzerland.
Evangelos TerposDepartment of Clinical Therapeutics, School of Medicine, University of Athens, Athens, Greece.
Gabriele IhorstClinical Trials Unit, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Heike ReinhardtDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Gerd WalzDepartment of Nephrology and Primary Care, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Ralph WäschDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Monika EngelhardtDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. monika.engelhardt@uniklinik-freiburg.de.
Stefan ZschiedrichDepartment of Nephrology and Primary Care, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. stefan.zschiedrich@uniklinik-freiburg.de.
University of Freiburg · DEUniversity Medical Center Freiburg · DENational and Kapodistrian University of Athens · GRUniversity Hospital of Basel · CH

Funding

Celgene 1095969Deutsche Krebshilfe 111424
6 · The paper itself

Abstract

backgroundThe estimated glomerular filtration rate (eGFR) is clinically used to approximate renal function and adapt drug dosage. Multiple myeloma is a hematological disease; its prognosis is largely influenced by renal function. We evaluated two commonly used GFR estimations, CKD-EPI and MDRD (CKD Epidemiology Collaboration; Modification of Diet in Renal Disease) in myeloma patients undergoing treatment with lenalidomide, a renally excreted immunomodulatory drug.

methodsWe prospectively studied 130 myeloma patients receiving lenalidomide treatment at our institution. At baseline and after 3 months, GFR estimations were performed based on the CKD-EPI and MDRD equations. We compared eGFR-dependent CKD staging and lenalidomide dosage assignments.

resultsInitially, most patients were classified as CKD stage I/II, using both equations. Comparison of baseline renal function via CKD-EPI and MDRD induced concordance of CKD staging in 83% of patients, while CKD-EPI improved CKD staging in 16% of patients (p = 0.11). CKD-EPI assigned 3% of patients to higher lenalidomide dosing as opposed to MDRD. Both equations showed improved eGFR after 3 months of lenalidomide treatment.

conclusionsIn our multiple myeloma patient cohort, CKD-EPI and MDRD led to similar CKD staging with minor differences in lenalidomide dosage assignment. Consistent with previous studies, eGFR improved under lenalidomide treatment. To standardize GFR estimation in myeloma patients, we suggest using the CKD-EPI equation.

Indexed as

Glomerular Filtration RateAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkersCreatinineDrug Dosage CalculationsFemaleHumansKidneyLenalidomideMaleMiddle AgedModels, BiologicalMultiple MyelomaAntineoplastic AgentsBiomarkersCreatinineLenalidomideChronic Kidney Disease-Epidemiology Collaboration (CKD-EPI)eGFRLenalidomideModification of diet in renal disease (MDRD)Multiple myeloma

Identifiers

PMID30128942
OpenAlexW2888091058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.